Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORE-PAIN
NCT06051227Phase 3Terminated
- Sponsor
- University of Amsterdam
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl citrate nasal spray and esketamine in acute pain (4 arms), sponsored by University of Amsterdam. Primary endpoint: Change in pain score as measured with Numeric Rating Scale (NRS) at 10 minutes. Started Jan 2024; status: terminated.
02
Drugs
fentanyl citrate nasal sprayesketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT06051227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06051227.